Wave Life Sciences schedules October 27 results for Wave Life Sciences stock

Published on 10/25/2026 at 13:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 2.27 million versus USD 7.45 million expected. October 27 is the next date for Wave Life Sciences stock.

Upcoming results and pipeline milestones

Wave Life Sciences scheduled its third-quarter review for October 20, 2026.
Its WVE-006 plan covers a two-year registrational trial with a one-year interim analysis.
Wave Life Sciences stock was last at EUR 2.84 on October 23, 2026 on Tradegate.
The company set its virtual research day for November 4, 2026.

WVE, US94352A1043, Illustration mit AI erstellt.

Wave Life Sciences (ISIN US94352A1043) scheduled its third-quarter 2026 results review for October 27, 2026, at 8:30 a.m. ET. The company disclosed the date on October 20 through Wave Life Sciences. The webcast will combine financial results with business updates, giving investors a defined checkpoint for the RNA medicines pipeline.

Three milestones shape the pipeline

Wave's recent announcements point to a development strategy built around clinical progress and regulatory preparation. On October 1, 2026, the company said the FDA supported a two-year registrational trial for WVE-006, with a one-year interim analysis that could support accelerated approval, according to Wave Life Sciences. On October 13, the company announced a presentation scheduled for October 20 at 9:45 a.m. ET, and on October 20 it scheduled the October 27 results review through GlobeNewswire.

What does October 27 add?

The answer will depend on whether the third-quarter update adds measurable progress to the existing clinical timetable. Wave's homepage identifies WVE-006 for alpha-1 antitrypsin deficiency, WVE-007 for obesity and WVE-008 for liver disease as key programs, while its latest reported second-quarter revenue was USD 2.27 million and net loss was USD 69.36 million. The revenue figure was down from USD 38.25 million in the first quarter, while cash stood at USD 368.01 million at June 30, 2026. These figures frame the results as a test of both pipeline execution and financial resources.

Two dates define the next steps

The October 27 webcast is the next scheduled company event, followed by Wave's virtual research day on November 4, 2026. The October 20 release describes the research day as a separate event, so the two dates offer distinct opportunities for updates on financial performance and clinical programs.

Stock stays in clinical focus

The last available German venue quote put Wave Life Sciences stock at EUR 2.84 on October 23, 2026 on Tradegate. The company also reported that WVE-006 data from its 600 mg monthly multidose cohort were planned for the fourth quarter of 2026, keeping clinical execution central to the investment case. The further course of trading is shown by the continuously updated real-time quote of Wave Life Sciences stock.